Medtronic earns Medicare, FDA wins for MiniMed 780G with Instinct sensor, including for type 2 diabetes

Medtronic (NYSE: MDT)+ today announced three U.S. milestones expanding access to its MiniMed 780G automated insulin delivery system.

Drug Delivery Business News, reports today that the company announced Medicare access for MiniMed 780G paired with the Instinct sensor made by Abbott, FDA clearance for the pairing for insulin-requiring type 2 diabetes and FDA clearance for the system’s use with ultra rapid-acting insulins.

Medtronic and Abbott entered a collaboration in August 2024 to pair insulin delivery and continuous glucose monitoring (CGM) technologies. Medtronic (soon to be a standalone company called MiniMed) launched the MiniMed 780G with the Instinct sensor made by Abbott late last year. The company further advanced the integrated offering with FDA 510(k) clearance for its MiniMed Go app for multiple daily injections (MDI) last month.

Sign up for Blog Updates